Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Todd Milne

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Clinical Journal of the American Society of Nephrology : CJASN|December 17, 2020
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical TrialJohn P Hanrahan, Ian H de Boer, George L Bakris, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2018
Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of DiseaseJenny V Tobin, Daniel P Zimmer, Courtney Shea, et al.
Frontiers in Pharmacology|April 24, 2020
Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory DiseaseDaniel P Zimmer, Courtney M Shea, Jenny V Tobin, et al.
Plos One|November 12, 2015
Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In VivoSheila Ranganath, Ashok Bhandari, Nicole Avitahl-Curtis, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Clinical Journal of the American Society of Nephrology : CJASN|December 17, 2020
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical TrialJohn P Hanrahan, Ian H de Boer, George L Bakris, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2018
Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of DiseaseJenny V Tobin, Daniel P Zimmer, Courtney Shea, et al.
Frontiers in Pharmacology|April 24, 2020
Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory DiseaseDaniel P Zimmer, Courtney M Shea, Jenny V Tobin, et al.
Plos One|November 12, 2015
Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In VivoSheila Ranganath, Ashok Bhandari, Nicole Avitahl-Curtis, et al.
Pageof 2